Navigation Links
$16.8 million study will breathe new life into cancer battle
Date:6/18/2009

University of Manchester scientists are among a multinational collaborative group to have been awarded 12 million for cancer research by the European Union.

The research will focus on tumour hypoxia, which describes an oxygen-deprived state that is common to all solid tumours.

Hypoxia causes a huge problem in cancer therapy because hypoxic cells are resistant to radiotherapy and most forms of chemotherapy; as a result, patients with hypoxic tumours respond less well to treatment.

Furthermore, hypoxia also appears to increase the chance that a tumour will spread and form metastases in other parts of the body. If a tumour begins to spread to other areas it becomes much more difficult to treat and so most cancer-related deaths are associated with metastases.

Recent advances in biological research have meant that there is now a greater understanding of the process of metastasis and why hypoxia plays such a key role. The researchers in this study aim to build on these advances and translate biological findings into clinically relevant treatments that will ultimately lead to improved patient response.

The Manchester team, led by Dr Kaye Williams in the School of Pharmacy and Pharmaceutical Sciences, will investigate how hypoxia changes cell behaviour and makes them more likely to metastasise. The scientists will then examine how these events can be targeted using specific therapies.

Further collaborative studies will attempt to develop novel ways of identifying patients with hypoxic tumours, which will mean their anti-cancer treatment can be tailored towards their specific tumour type.

"Working alongside our internationally leading colleagues within the rest of the research consortium, there is a huge opportunity to develop new therapies and imaging strategies that will benefit many cancer patients with solid malignancies," said Dr Williams.

"Hypoxia causes huge problems in the effective treatment of many cancers, so understanding how it alters the behaviour of cells will be a major breakthrough and should help us to develop therapeutic interventions that will make tumours less deadly."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Cardinal Health Foundation Awards $1 Million to Fund Patient Safety Initiatives
2. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
3. Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
4. GlaxoSmithKline Opens $600million Vaccine Plant In Singapore
5. GE Launches Program to Doctors, Hospitals to Accelerate EMR Adoption; First $100 Million of healthymagination Commitment
6. PDI, Inc. Announces New Business Wins Exceeding $18 Million
7. Saint Thomas Health Services Partners With Curaspan on Patient Flow Initiative Resulting in Estimated Savings of Nearly $6 Million
8. Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
9. Former Gov. Bill Clements Makes Historic Gift to UT Southwestern With $100 Million Transformative Contribution
10. With 15 Million Kids Expected to Go Hungry This Summer, Boys & Girls Clubs of America Partners With Morgan Stanley to Launch Million Meal Summer Program
11. State to Invest $11.1 Million in Expansion of Doylestown Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in ... , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass ... will help provide scholarship funds for area students and operating support to UNCF-member ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame ... (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking ... prescription drug plan (Part D) need to make changes during this period order for ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein Weltführer ... bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific Corporation ... agreement to acquire certain manufacturing assets and capabilities of ... NVC) advanced biological tissue business, as well as a ... $75 million in cash. The Neovasc advanced biological tissue ... the Boston Scientific Lotus™ Valve System. * Upon ...
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
Breaking Medicine Technology: